Specialty medical homes (SMHs) are a new health care model in which a multidisciplinary team and specialists manage patients with chronic diseases. As part of a large integrated payer-provider network, we formed an inflammatory bowel diseases (IBDs) SMH and investigated its effects on health care use, disease activity, and quality of life (QoL).
medical homes. Designed to improve patient experience, enhance health care quality, and decrease costs, these models have been deployed in primary care, but have yet to be tested in specialty care. IBDs are chronic diseases that often develop in the first 3 decades of life and primary medical care is provided by the gastroenterologist. Because of the unique health care needs of this population, an IBD specialty medical home (SMH) would provide a novel model in which the gastroenterologist serves as the principle care provider.
In conjunction with the University of Pittsburgh Medical Center (UPMC) Health Plan (HP), we designed and established an IBD SMH, designated UPMC Total Care-IBD. 5 Initiated in July 2015 with ongoing active enrollment, UPMC Total Care-IBD has assumed care for more than 650 patients to date. We aimed to investigate the feasibility, durability, and impact of Total Care-IBD after 1 year of enrollment and treatment. The primary outcome of interest was unplanned care, and secondary outcomes were QoL and disease activity.
Materials and Methods

University of Pittsburgh Medical Center Total Care-Inflammatory Bowel Disease Design
The UPMC is an integrated delivery and finance system, operating both a large academic health system and a health insurance plan that covers more than 3 million members, predominantly in western Pennsylvania. Details of the design, implementation, and flow of UPMC Total Care-IBD program have been published previously. 5, 6 The multidisciplinary care team included a social worker, dietitian, schedulers, nurse coordinators, and advanced practice providers, and was led by a gastroenterologist (M.R.) and psychiatrist (E.S.). The gastroenterologist became the principle care provider for this population and coordinated the total care of the patient. Some of the UPMC Total Care-IBD staff (eg, the nurse coordinator, advanced practice provider, dietitian, and social worker) were paid for by the HP. The Total Care-IBD team routinely coordinated care with chronic pain specialists, colorectal surgeons, and peervolunteer specialists (IBD Connect), and relied on nurse and social worker home visits to the highest utilizer patients, open-access scheduling, remote monitoring, and telemedicine. Weekly meetings between the payer and providers reviewed patient care plans, outcomes, and utilization data.
University of Pittsburgh Medical Center Total Care-Inflammatory Bowel Disease Enrollment
Enrollment criteria included the following: member of UPMC HP insurance product (ie, commercial, Medicare, Medicaid, Medicaid/Medicare dually eligible); a confirmed diagnosis of CD or UC; and age 18 through 60 years.
Study Population
To assess the impact of UPMC Total Care-IBD in a proof-of-concept manner, we conducted a quasiexperimental, time-interrupted study of patients enrolled in Total Care-IBD. Patients underwent informed consent; all data were collected prospectively and the study was approved by the Institutional Review Board at the University of Pittsburgh (protocol 15100396). Patients who enrolled in Total Care-IBD in the first calendar year (June 2015 to July 2016) with at least 365 days of follow-up evaluation were eligible for study inclusion. Patients were excluded if they were not enrolled in Total Care-IBD, if they changed to a non-UPMC HP product before 365 days of follow-up evaluation, or if they had fewer than 365 days of follow-up evaluation.
Patient and Disease Characteristics
Patient demographics and disease characteristics were collected at the first UPMC Total Care-IBD encounter and included age, sex, body mass index, ethnicity, smoking status, and insurance status (commercial or governmental product). IBD characteristics included disease type (CD or UC), disease duration, prior IBD-related surgery, and prior or present ostomy or ileal pouch-anal anastomosis.
Disease Activity, Quality of Life, and Mental Health Metrics Patient-reported disease activity scores (HarveyBradshaw Index [HBI] for CD and UC activity index [UCAI] for UC), disease-related QoL metric (short inflammatory bowel disease questionnaire [SIBDQ]), and depression and anxiety screening metrics (patient health questionnaire [PHQ]-9 and generalized anxiety disorder [GAD]-7, respectively) were collected prospectively at each visit. [7] [8] [9] [10] [11] All patients entering Total Care-IBD were evaluated initially by the gastroenterologist, dietitian, social worker, advanced practitioner, and registered nurse. If scores on mental health metrics indicated significant mental health impairment (PHQ-9 or GAD-7 ! 10), the Total Care-IBD social worker or psychiatrist (E.S.) performed a full psychiatric evaluation for a potential diagnosis of comorbid behavioral health disorders. Other determinants to meet with the social worker, psychiatrist, and/or an integrated pain anesthesiologist were the presence of other comorbid psychiatric conditions, chronic pain, as well as the discretion of the team (eg, patients requiring social assistance or stress management). Active IBD was defined by an HBI or UCAI score greater than 4; poor QoL, considered at an SIBDQ less than 50; and depression or anxiety, PHQ-9 or GAD-7 greater than 10, respectively.
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Medications IBD medications were collected prospectively at each Total Care-IBD visit and included mesalamines, systemic corticosteroids, thiopurines (azathioprine and 6-mercaptopurine), methotrexate, anti-tumor necrosis factor (TNF) (infliximab, adalimumab, certolizumab pegol, golilumab), anti-integrin (natalizumab, vedolizumab), and anti-interleukin 12/23 (ustekinumab) agents. Other medications including opioids and antidepressants (tricyclic antidepressants, selective-serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors) were similarly recorded. Dosing, intervals, and medications for other indications were not documented prospectively.
Health Care Utilization
At each Total Care-IBD encounter, patient-reported interim health care utilization including endoscopy, radiography (computed tomography or magnetic resonance imaging for IBD purposes), IBD-related surgery, Emergency Department (ED) visits, and hospitalizations for IBD indications were recorded. For comparison, ED visits and hospitalizations in the 3 months and year before enrollment were recorded via manual chart review.
Primary Outcomes
The primary outcome of interest was unplanned health care utilization (inpatient hospitalization and/or ED visits) in the 1 year after Total Care-IBD enrollment. We compared rates of utilization in the 1 year before enrollment with the 1 year after an individual's Total Care-IBD engagement. For purposes of evaluating the rapidity of impact of Total Care-IBD, we also subdivided and compared 3-month utilization before and after an individual's enrollment.
Secondary Outcomes
Secondary outcomes included changes in patientreported disease activity, disease-specific QoL, depression scores, and stress/anxiety metrics. We also aimed to determine baseline predictors of postenrollment utilization using demographic, clinical, and disease-related factors. To examine for heterogeneity of treatment effect the SIBDQ, PHQ-9, and GAD-7 baseline scores were divided into quartiles and the change in each metric by quartile was examined.
Statistical Analysis
Categoric variables were compared using the chi-square and Fisher exact test where appropriate. Continuous variables were compared using the Student t test or 1-way analysis of variance for normally distributed variables and the Wilcoxon rank-sum or sign-rank test for nonparametric variables.
Logistic regression modeling to determine baseline predictors of post-enrollment health care utilization was performed. Regression imputation was performed for predictor variables with more than 5% missing data. Variables with P < .1 on univariate testing were included in a multivariate model. Significance was considered at P .05 unless otherwise stated.
All authors had access to the study data and reviewed and approved the final manuscript.
Results
Patient Cohort
There were 346 patients enrolled in the first year of Total Care-IBD and 322 met the inclusion criteria. The majority (57.6%) were female, Caucasian (81.1%), nonsmokers (82.1%), with a mean age of 34.6 years ( Table 1) . Most patients (77.3%) had a commercial product of UPMC HP insurance.
The majority (62%) of patients had CD and nearly half (44.4%) had prior IBD-related surgery, with 12.1% undergoing 3 or more surgeries. Nearly one fifth (21.2%) of CD patients were actively smoking. The majority (59%) of CD patients had received anti-TNF therapy previously. At enrollment, 14.1% of CD patients were receiving corticosteroids, 43.9% (n ¼ 87) were on a biologic agent, of whom 40% (n ¼ 35) were on a concomitant immunomodulator.
Of UC patients, 12.1% had undergone prior colectomy. At enrollment, 19.4% of UC patients were receiving corticosteroids, 25% (n ¼ 31) were receiving a biologic agent, of whom 38.7% (n ¼ 12) were on combination therapy with an immunomodulator.
Compared with UC, CD patients had a significantly longer disease duration (P ¼ .02), more patients with prior IBD surgery (P < .0001), an ostomy (P ¼ .03), more historical and current anti-TNF use (both P < .0001), and more combination therapy (P ¼ .05).
At enrollment, nearly half (49.1%) of patients had a poor QoL (SIBDQ < 50), 45.6% of CD patients qualified as active disease (HBI > 4), and 31.5% of UC patients had clinically active disease (UCAI > 4). Nearly a third of total patients (28.3%) met the criteria for depression on PHQ-9 screening at enrollment (PHQ-9 ! 10) and 18.6% met the criteria for significant stress or anxiety (GAD-7 ! 10). Of patients with inactive disease, 9% met the criteria for depression.
Health Care Utilization
In the year before Total Care-IBD, there were 510 ED visits by 112 patients and 209 hospitalizations by 83 patients (Figure 1) . In the year after enrollment, there was a significant reduction in the number of both ED visits (269 events by 98 patients; P < .0001) and hospitalizations (134 events by 67 patients; P ¼ .008).
The impact of Total Care-IBD on unplanned care was evident shortly after patient enrollment. Within 3 months there was a significant decrease in ED utilization and hospitalizations compared with the same time period immediately preceding enrollment into Total Care-IBD: 226 ED visits by 79 patients and 92 hospitalizations by 46 patients in the 3 months before entry, and 32 ED visits by 23 patients and 19 hospitalizations by 17 patients after entry (both P < .0001).
Only 18 of the patients enrolled in Total Care-IBD in the first year discontinued. Fourteen changed to non-UPMC HP insurance, and 4 patients moved to another state. Excluded patients showed relatively low resource utilization. Three patients had a single ED visit each in the year before Total Care-IBD and 1 patient had a single hospitalization after enrollment.
In the year before enrollment, 7.5% of patients had an intestinal resection, 42.7% had at least 1 radiographic study, and 51.8% underwent at least 1 endoscopic procedure. In the year after enrollment more patients underwent an intestinal resection (10.6%; P ¼ .22), but fewer had radiographic studies (34.1%; P ¼ .06) and endoscopic procedures (43.5%; P ¼ .08).
Interventions
In the first year of Total Care-IBD, 255 patients had more than 1 clinic visit and were available for patientreported intervention assessment. Of these, 32.9% were prescribed at least 1 new steroid prescription. Maintenance medication changes included starting an immunomodulator in 38.4% (thiopurine, n ¼ 79; methotrexate, n ¼ 19) and 27.5% newly initiated or changed a biologic agent (anti-TNF, n ¼ 54; anti-integrin, n ¼ 12; ustekinumab, n ¼ 4). Anti-TNFs were stopped in 54 patients and 3 patients were transitioned to anti-integrin therapy. Thiopurines were stopped in 39 patients, of whom 4 switched to methotrexate while 11 patients on methotrexate at enrollment stopped with 4 changing to thiopurines. The reason for stopping or switching IBD medications was not always readily recorded, but most indications were because of patient intolerance, lack of efficacy, or a desire to de-escalate therapy. Of the patients who entered Total Care-IBD, 9 were weaned off of opioids successfully and have remained free of narcotics.
The mean number of clinic visits was 3.4 AE 4.6 (maximum, 51). Nearly one third (34.8%) of patients met with a psychiatrist at least once and 73.3% met with the social worker. Of patients who met with the psychiatrist, the mean number of visits was 4.4 AE 5.8 (maximum, 37) and 7.8% of patients engaged in telepsychiatry sessions. The mean number of social work visits was 5.2 AE 8.2 (maximum, 54). The integrated pain specialist was used by 7.8% of patients with a mean number of 7.0 AE 5.3 visits.
Disease Activity, Quality of Life, and Mental Health Metrics
Over the first year of Total Care-IBD, there was a significant reduction in disease activity scores for both CD (median HBI, 4 to 3.5; P ¼ .002) and UC (median UCAI, 4 to 3; P ¼ .0003) ( Table 2 ). The highest quartiles at enrollment experienced the largest reduction for HBI (median HBI, 9 to 6; P < .001) and UCAI (median UCAI, 9 to 5; P < .001) (Figure 2) .
Similarly, depression (median PHQ-9, 6 to 5; P < .0001) and anxiety (median GAD-7, 4 to 4; P ¼ .02) metrics were reduced significantly over the first year. The most extreme quartiles for both mental health metrics showed the most improvement (median PHQ-9, 16 to 12; P < .001; and median GAD-7, 14 to 11; P < .001).
Finally, QoL scores improved significantly over the first year (median SIBDQ, 50 to 51.8; P < .0001) and the lowest quartile showed the largest improvement (median SIBDQ, 31 to 39; P < .001).
In sum, there was moderate, but significant, improvement in IBD activity, depression, anxiety, and QoL scores after enrollment in the medical home. The most pronounced impact on patient-reported outcomes Figure 1 . IBD-related health care utilization in the 3-month and 1-year period before and after SMH enrollment. Average of scores in all visits after the first visit. b A total of 61 patients had incomplete GAD-7 at enrollment.
was realized in the highest quartile of disease severity, mental health impairment, and poorest QoL.
Predictors of Health Care Utilization
Multivariable logistic regression of health care utilization (ED or hospitalization) in the year after enrollment showed that baseline steroid requirement (adjusted odds ratio [AOR], 2.72; 95% CI, 1.32-5.66; P ¼ .007), opioids at enrollment (AOR, 3.20; 95% CI, 1.32-7.78; P ¼ .01), and low QoL (AOR, 4.44; 95% CI, 1.08-18.25; P ¼ .04) remained independently predictive of post-enrollment health care utilization (Table 3) . On univariate analysis, a high PHQ-9 score (OR, 2.60; P ¼ .004) was associated with future utilization, but in the multivariate model, the 2 median quartiles (AOR, 0.42; 95% CI, 0.18-0.99; P ¼ .05; and AOR, 0.22; 95% CI, 0.07-0.68; P ¼ .008) were at significantly decreased risk of utilization compared with the lowest quartile, and the highest PHQ-9 was no longer statistically associated (AOR, 0.51; 95% CI, 0.13-2.01; P ¼ .33).
Notable nonsignificant independent predictors of post-enrollment health care utilization included active smoking, insurance (Medicaid compared with commercial), number of prior anti-TNFs, and baseline anxiety metrics.
Discussion
Implementing a patient-centered SMH for the care of IBD patients is feasible and results in a significant reduction in unplanned care, an improvement in disease activity, and better QoL. This SMH could serve as a template for new models of health care. The results highlight the opportunity for deeper collaboration between payers and providers in which aligned incentives could be sufficient to encourage investment in such alternative models.
Patients enrolled in Total Care-IBD had high rates of health care utilization that decreased significantly in the year after enrollment. The reduction in unplanned care and QoL improvement was owing to 3 core elements:
(1) stratification of the determinants that drove health utilization, (2) care plans that used the multidisciplinary team, and (3) the partnership between the provider group and health plan around the collective care of a population of patients. Stratifying patients by biological, social, and behavioral risk factors for high health care resource utilization and poor QoL allowed individualized care plans and resource allotment.
Risk factors independently predictive of health care utilization after enrollment included corticosteroid requirement, opioid use, and poor QoL scores. Corticosteroids may be a surrogate marker for more severe IBD whereas chronic opioid use may indicate pain issues, addiction, or narcotic bowel syndrome. We successfully weaned a small cohort of patients off opioids. Despite the aggressive multidisciplinary approach of the IBD SMH, those patients continuing to use opioids had high rates of unplanned care and poor QoL. These findings corroborate previous results from our group as well as others. [15] [16] [17] [18] Anxiety and depression rates were comparable with published rates. 19, 20 Psychosocial complexity influenced the IBD course. 21 Less than half of our cohort had active IBD at baseline with psychosocial factors adversely impacting QoL and medical utilization. The Total Care-IBD program integrated behavioral care into management plans that improved anxiety, depression, QoL, and reduced unplanned care.
Several other programs have designed novel approaches to improving care and reducing cost for IBD populations. The Division of Digestive Disease at the University of California Los Angeles has introduced a comprehensive, integrated, and holistic approach to value-based care in the chronic disease management of IBDs, with the development of the "Value-Quotient" for value-based and cost-effective IBD management.
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The Illinois Gastroenterology Group developed Project Sonar, a care management solution for patients with IBD. Project Sonar uses nurse care managers and physician medical directors in a team approach to coordinate care for patients with IBD, along with clinical decision support and patient engagement, and recently partnered with a national payer to create a specialist intensive medical home. [26] [27] [28] Although these programs have different design elements from the UPMC IBD SMH, the reliance on multidisciplinary care of a chronic disease population and partnership with an insurance plan is similar.
Our study had several limitations. The greatest limitation was the lack of a control group to compare SMH intervention with routine clinical IBD care. We initially planned to compare Total Care-IBD patients with those not enrolled, however, the most complex and highest utilizer UPMC Health Plan IBD patients were enrolled disproportionately into Total Care-IBD. Although this was the intent of the program, the non-Total Care-IBD patients were of lower complexity and utilizers and could not serve as an accurate comparator group. This initial patient complexity was similar to most tertiary referral practices, but nonetheless may limit the generalizability of the study findings. Another significant limitation was that we lacked important data on the number of clinic visits, telephone calls, electronic messages, and total cost of care from the full cohort for the 1 year before medical home enrollment. A significant proportion of our patients did not have UPMC HP insurance for a full year before enrollment in the medical home, which did not allow preenrollment and post-enrollment analyses on these parameters. Data on medical comorbidities were not collected routinely and may have influenced unplanned care outcomes. Scalability and reproducibility to other providers and health care systems also may be limited. We acknowledge that the integrated delivery and finance system of UPMC is unique and other health care systems may face additional challenges in payerprovider collaboration and securing payer fiscal support. We assessed outcomes at 1 year, which may be too short of a duration to see a lasting impact and our results may represent early regression to the mean. Ultimately, longer follow-up evaluation, comparison with a propensity-matched cohort, data on total cost of care, and return on investment will be evaluated in the future. Despite these limitations, the enrollment of a population of IBD patients from a single payer with prospective collection of data, a high retention rate, and assessment of outcomes is unique and allowed meaningful analyses.
In conclusion, a patient-centered specialty medical home for IBD patients is a feasible alternative health care delivery model that reduced health care utilization, improved disease activity, and led to a better QoL.
